Twilight Of The Opioids? Label Updates, Review Changes May Have Less Impact Than Shrinking Pipeline
Executive Summary
Many prescribers don’t read drug labels, meaning they may not see the new warnings and recommendations in the immediate- and extended-release opioid labels, says Brandeis’ Kolodny. Meanwhile, as the Senate advances a bill that would allow comparative review of opioids, they make up a smaller amount of the drug development landscape.